CB CD34+ cells with up-regulated hTERT expression allowed multilineage differentiation in NOD/SCID B2m-/- mice bone marrow
Group . | No. mice in group . | CD33/15+, % . | CD19+, % . | CD34+, % . |
|---|---|---|---|---|
| dGFP+ | 9 | 20 ± 12 | 85 ± 6.9 | 12 ± 3.8 |
| GFP+ | 8 | 16 ± 8.0 | 84 ± 10 | 17 ± 11 |
| Mock | 5 | 18 ± 4.9 | 85 ± 4.0 | 16 ± 6.1 |
Group . | No. mice in group . | CD33/15+, % . | CD19+, % . | CD34+, % . |
|---|---|---|---|---|
| dGFP+ | 9 | 20 ± 12 | 85 ± 6.9 | 12 ± 3.8 |
| GFP+ | 8 | 16 ± 8.0 | 84 ± 10 | 17 ± 11 |
| Mock | 5 | 18 ± 4.9 | 85 ± 4.0 | 16 ± 6.1 |
Sublethally irradiated NOD/SCID B2m-/- mice received transplants of sorted dGFP+, GFP+, or mock-transduced cells at 1 × 105 cells per animal via tail-vein injection. At 6 weeks after transplantation, the human-cell engraftment and lineage differentiation were assessed in mice bone marrow. Data shown are the averages and standard deviations of the percentages of myeloid, B lymphoid, and CD34+ cells in the CD45+ human cells.